Simtuzumab treatment of advanced liver fibrosis in <scp>HIV</scp> and <scp>HCV</scp>‐infected adults: results of a 6‐month open‐label safety trial

Abstract

In this open-label, pilot clinical trial, simtuzumab treatment was well-tolerated in HCV- and HIV-infected subjects with advanced liver disease. Putative modulation of TGF-β3 and IL-10 pathways during simtuzumab treatment merits investigation in future trials.